Returning guest Dr. Scot Ebbinghaus discusses the recent (Jan 2020) FDA approval of Merck’s KEYTRUDA® (pembrolizumab) for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma In situ with or without papillary tumors who are Ineligible for or have elected not to undergo cystectomy.
Dr. Scot Ebbinghaus joined Merck Research Labs Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development with responsibilities for overseeing the Keytruda (pembrolizumab) development program as well as responsibility for the development of Lynparza (olaparib) and selumetinib in collaboration with Astra Zeneca. Prior to joining Merck, Dr. Ebbinghaus was an Associate Professor at the University of Arizona in the Department of Medicine, Section of Hematology/Oncology.Dr. Ebbinghaus earned his M.D. degree from the University of Missouri-Kansas City, completed his residency in Internal Medicine and his fellowship in Hematology-Oncology at the University of Alabama-Birmingham. Dr. Ebbinghaus has published over 40 manuscripts, and 5 book chapters in the field of Oncology. In addition to his current responsibilities at Merck, Dr. Ebbinghaus is an attending physician at Fox Chase Cancer Center in Philadelphia in the Thoracic Oncology unit.